ICU
SeaStar Medical Holding Corporation Common Stock
stock NASDAQ

The primary issue is that unless there is a cash pay component (elective), a “buy-and-bill” drug component, or ASC ownership, the non-health system players are severely handicapped. The primary problem is that health systems can afford to pay comp so high that they are losing on the individual doctor (think laborists, ER physicians, etc.), but the downstream revenues from the NICU, ICU, highly specialized surgical, are all worth it for the system.
What you’ll really see isn’t a flood of physicians, it’s a concentration. Most Medicaid heavy hospital will close major divisions due to the govt reimbursement not being enough to cover their costs. For example, L&D - there is a massive shortage, bc the downstream from childbirth is a fraction when Medicaid is paying. The cost is too high.
We don’t have a PE problem, we have a cost problem. The cost issue isn’t rooted in reimbursement (although that is a problem), it’s the regulatory and technical (EHR) billing and documentation burden. You will hear that 4% of revenue (not profit, REVENUE) is best in class RCM for healthcare. It isn’t, that’s leaving out a bunch of tangential cost. It’s 10% of revenue to even try to document, bill, and collect. You patient facing staff will be 55-70% assuming high efficiency), so you’ve spent ~70% of your top line before you consider rent/utilities, medical malpractice, administration. Make all of that super efficient and you’re sitting at 10% margin.
But it’s never that efficient, and no system has the highest reimbursement, and, and, and. Unless you want to be a urologist or a gastroenterologist - the odds of having a solid income/building something as a physician are slim.

If you sort the ASX list by share price or by market cap, the bottom of the list would have many of these. For example, ICU (appropriate ticker).
Or, do you mean more well-known companies that could be circling the drain, like IMM?

The primary issue is that unless there is a cash pay component (elective), a “buy-and-bill” drug component, or ASC ownership, the non-health system players are severely handicapped. The primary problem is that health systems can afford to pay comp so high that they are losing on the individual doctor (think laborists, ER physicians, etc.), but the downstream revenues from the NICU, ICU, highly specialized surgical, are all worth it for the system.
What you’ll really see isn’t a flood of physicians, it’s a concentration. Most Medicaid heavy hospital will close major divisions due to the govt reimbursement not being enough to cover their costs. For example, L&D - there is a massive shortage, bc the downstream from childbirth is a fraction when Medicaid is paying. The cost is too high.
We don’t have a PE problem, we have a cost problem. The cost issue isn’t rooted in reimbursement (although that is a problem), it’s the regulatory and technical (EHR) billing and documentation burden. You will hear that 4% of revenue (not profit, REVENUE) is best in class RCM for healthcare. It isn’t, that’s leaving out a bunch of tangential cost. It’s 10% of revenue to even try to document, bill, and collect. You patient facing staff will be 55-70% assuming high efficiency), so you’ve spent ~70% of your top line before you consider rent/utilities, medical malpractice, administration. Make all of that super efficient and you’re sitting at 10% margin.
But it’s never that efficient, and no system has the highest reimbursement, and, and, and. Unless you want to be a urologist or a gastroenterologist - the odds of having a solid income/building something as a physician are slim.

If you sort the ASX list by share price or by market cap, the bottom of the list would have many of these. For example, ICU (appropriate ticker).
Or, do you mean more well-known companies that could be circling the drain, like IMM?